FDA publicly posted test performance data from four more antibody, or serology, test kits on open.fda.gov from its independent performance validation study effort with NCI (The Cancer Letter, May 15, 2020).
In a survey conducted by the American Cancer Society Cancer Action Network survey of cancer patients and survivors, 87% of respondents said the COVID-19 pandemic had affected their health care in some manner, up from 51% in an April survey.
A team of data scientists and cancer doctors from the University of Michigan Rogel Cancer Center and the U-M School of Public Health developed a free, web-based application to compare the long-term risk for a patient whose cancer treatment was postponed.
Genentech, a member of the Roche Group, has launched a phase III, randomized, double-blind, multicenter study (REMDACTA) to evaluate the safety and efficacy of Actemra (tocilizumab) plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalized patients with severe COVID-19 pneumonia.
An observational study of more than 3,000 patients hospitalized with COVID-19 at Hackensack Meridian Health has shown that hydroxychloroquine doesn't improve survival for hospitalized patients.
UCLA researchers have launched a phase II trial that uses TMPRSS2, a hormone suppressor commonly used to treat prostate cancer, to improve clinical outcomes for men infected with COVID-19.
GRYT Health and Bristol Myers Squibb Co. developed the COVID Advocacy Exchange, a virtual platform to connect patient advocacy organizations, patients, policy makers, healthcare practitioners, and industry in the exchange of information.
Researchers from MSK Kids at Memorial Sloan Kettering Cancer Center found that children with cancer are not at a higher risk of being affected by COVID-19.
An immunotherapy combination, rintatolimod and interferon alfa, first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some solid tumor cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.
Two component institutions of Heartland Cancer Research NCORP have created drive-through laboratory services for outpatients during the COVID-19 crisis.
